incretin mimetics (GLP-1 analogues) and incretin enhancers (DPP-4 inhibitors) are now available for the treatment of Type 2 diabetes. Initial combination therapy with a DPP-4 inhibitor ...

The following is a summary of "Adherence and persistence among people with type 2 diabetes newly initiating oral semaglutide ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

Reduction seen in recurrent nephrolithiasis events for those receiving SGLT-2 inhibitors vs GLP-1 RAs, DPP-4 inhibitors. HealthDay News — For patients with nephrolithiasis, sodium-glucose ...

Dipeptidyl peptidase 4 (DPP-4) inhibitors block the degradation of the body's own endogenous GLP-1, as well as other peptide hormones such as glucose-dependent insulinotropic peptide (GIP).

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose ... to linagliptin if used in combination. Diuretics, steroids ...

For patients with comorbid gout, SGLT2 inhibitor use was significantly associated with a 33% lower risk of recurrence and outperformed GLP-1 receptor agonists and DPP-4 inhibitors. The risk for ...